JAK2 and leukemia: Although ruxolitinib has not been widely tested in pediatric leukemia, preclinical studies and early-phase clinical trials suggest that it holds promise as a treatment for pediatric leukemias with JAK2 mutations or JAK-STAT pathway dysregulation.